Literature DB >> 11921664

Inflammatory and immune processes: the neglected villain of bioprosthetic degeneration?

P Human1, P Zilla.   

Abstract

In an attempt to avoid the destructive process of bioprosthetic heart-valve calcification associated with the use of glutaraldehyde, valves are today prepared using low concentrations of the crosslinking reagent. In this review, we summarize our findings and those of others that confirm that the immunogenicity of such tissue is not sufficiently masked and that a defined humoral response is indeed mounted against a repertoire of antigens unrelated to those associated with vascularized and non-cross-linked xenograft organs. We demonstrate the need for increased cross-linking of tissue to satisfactorily mitigate that response; furthermore, we examine the impact of increased cross-link density on the macrophage as antigen presenting cell with respect to its involvement in both tissue erosion and pannus overgrowth. Finally we present evidence for a role of circulating antibodies in bioprosthesis calcification.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11921664

Source DB:  PubMed          Journal:  J Long Term Eff Med Implants        ISSN: 1050-6934


  15 in total

Review 1.  In Search of the Ideal Valve: Optimizing Genetic Modifications to Prevent Bioprosthetic Degeneration.

Authors:  Benjamin Smood; Hidetaka Hara; David C Cleveland; David K C Cooper
Journal:  Ann Thorac Surg       Date:  2019-03-02       Impact factor: 4.330

Review 2.  Decellularized matrices for cardiovascular tissue engineering.

Authors:  Francesco Moroni; Teodelinda Mirabella
Journal:  Am J Stem Cells       Date:  2014-03-13

3.  Stability and function of glycosaminoglycans in porcine bioprosthetic heart valves.

Authors:  Joshua J Lovekamp; Dan T Simionescu; Jeremy J Mercuri; Brett Zubiate; Michael S Sacks; Narendra R Vyavahare
Journal:  Biomaterials       Date:  2005-09-06       Impact factor: 12.479

Review 4.  Small Diameter Xenogeneic Extracellular Matrix Scaffolds for Vascular Applications.

Authors:  Manuela Lopera Higuita; Leigh G Griffiths
Journal:  Tissue Eng Part B Rev       Date:  2019-11-27       Impact factor: 6.389

5.  Magnesium Presence Prevents Removal of Antigenic Nuclear-Associated Proteins from Bovine Pericardium for Heart Valve Engineering.

Authors:  Ailsa J Dalgliesh; Zhi Zhao Liu; Leigh G Griffiths
Journal:  Tissue Eng Part A       Date:  2017-03-10       Impact factor: 3.845

6.  Protein extraction and 2-DE of water- and lipid-soluble proteins from bovine pericardium, a low-cellularity tissue.

Authors:  Leigh G Griffiths; Leila Choe; Kelvin H Lee; Kenneth F Reardon; E Christopher Orton
Journal:  Electrophoresis       Date:  2008-11       Impact factor: 3.535

7.  Characterization of immunogenic Neu5Gc in bioprosthetic heart valves.

Authors:  Eliran Moshe Reuven; Shani Leviatan Ben-Arye; Tal Marshanski; Michael E Breimer; Hai Yu; Imen Fellah-Hebia; Jean-Christian Roussel; Cristina Costa; Manuel Galiñanes; Rafael Mañez; Thierry Le Tourneau; Jean-Paul Soulillou; Emanuele Cozzi; Xi Chen; Vered Padler-Karavani
Journal:  Xenotransplantation       Date:  2016-09-09       Impact factor: 3.907

8.  Immunoproteomic identification of bovine pericardium xenoantigens.

Authors:  Leigh G Griffiths; Leila H Choe; Kenneth F Reardon; Steven W Dow; E Christopher Orton
Journal:  Biomaterials       Date:  2008-06-02       Impact factor: 12.479

9.  Fine structure of glycosaminoglycans from fresh and decellularized porcine cardiac valves and pericardium.

Authors:  Antonio Cigliano; Alessandro Gandaglia; Antonio Junior Lepedda; Elisabetta Zinellu; Filippo Naso; Alessandra Gastaldello; Paola Aguiari; Pierina De Muro; Gino Gerosa; Michele Spina; Marilena Formato
Journal:  Biochem Res Int       Date:  2012-02-22

10.  Tissue engineered bovine saphenous vein extracellular matrix scaffolds produced via antigen removal achieve high in vivo patency rates.

Authors:  Manuela Lopera Higuita; Juan F Lopera Giraldo; Tiffany L Sarrafian; Leigh G Griffiths
Journal:  Acta Biomater       Date:  2021-06-27       Impact factor: 10.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.